Document is current

Any future updates will be listed below

Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin’s lymphoma

Crossref DOI link: https://doi.org/10.1007/s44313-025-00097-z

Published Online: 2025-11-21

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark